During a six-month chronic oral toxicity study of Sprague-Dawley rats, researchers found that the Caralluma fimbriata extract produced no deaths or treatment-related toxicities at three doses (100, 300, and 1000 mg/kg body weight). Additionally, no external, visceral, or skeletal fetal abnormalities were observed following a prenatal developmental toxicity study up to the maximum dose tested.
Published in the International Journal of Toxicology, the study was conducted by INTOX Pvt Ltd. “These assessments are great news for consumers looking for safe weight management support,” said Dr. Paul Clayton, chief scientific advisor at Gencor. “Together with its scientifically validated ability to reduce fat and suppress appetite, Caralluma fimbriata offers both safety and efficacy.”
Previously, two double blind, placebo-controlled clinical trials found statistically significant decreases in waist circumference in experimental groups taking the Caralluma Fimbriata extract compared to placebo groups.
Since 2006, Gencor has offered this patented extract of Caralluma fimbriata as an appetite suppressant under the brand name Slimaluma. Versatile for delivering a wide range of tastes and textures, Slimaluma can be used in beverages, smoothies, capsules, tablets, chocolates and meal replacements. Slimaluma is self-affirmed GRAS, certified Kosher and Halal, and available certified Organic.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.